National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lornoxicam (Xefo®) for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis

Rapid Review

Commenced Completed Outcome
23/06/2011 07/07/2011 Full Pharmacoeconomic Evaluation not Recommended